Relief Therapeutics’ CHF 15 Million Shares Private Placement

Pestalozzi advised H.C. Wainwright LLC on the deal, while VISCHER advised Relief Therapeutics.

RELIEF THERAPEUTICS Holding AG. a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced that it has entered into a definitive agreement with two U.S. institutional investors to purchase in a private placement an aggregate of 71,428,572 shares of Relief common stock at a purchase price of CHF 0.21 per share.

The aggregate gross proceeds from the private placement are expected to be approximately CHF 15 million, before deducting the placement agent fees and offering expenses payable by Relief. The private placement offering is expected to close on or about July 28, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Relief plans to use the net proceeds from the private placement to acquire additional assets to expand and diversify its drug pipeline, meet its obligations to pay potential milestone payments and for general corporate purposes.

The Pestalozzi team included Christian Leuenberger (Picture – Lead Partner – Capital Markets, Corporate/M&A), Severin Roelli (Partner – Corporate/M&A), Manu Ferro (Associate – Banking & Finance).

The VISCHER team led by partner Dr. Robert Bernet (Corporate/M&A) comprised Dr. Peter Kühn (Counsel, Corporate/M&A) and Christian Schneiter (Senior Associate, Banking & Finance).

Involved fees earner: Manu Ferro – Pestalozzi; Christian Leuenberger – Pestalozzi; Severin Roelli – Pestalozzi; Robert Bernet – VISCHER AG; Peter Kühn – VISCHER AG; Christian Schneiter – VISCHER AG;

Law Firms: Pestalozzi; VISCHER AG;

Clients: H.C. Wainwright & Co.; Relief Therapeutics;

Author: Federica Tiefenthaler